局部用米诺环素Foamix获得FDA批准,治疗数百万中度至重度痤疮患者

2019-10-19 不详 MedSci原创

以色列Foamix制药公司宣布,美国食品药品监督管理局(FDA)批准了其新型AMZEEQ(米诺环素,占4%)局部用泡沫剂,用于治疗9岁及以上的非结节性中度至重度寻常性痤疮的炎性病变,并且是首个获得FDA批准的局部米诺环素。

以色列Foamix制药公司宣布,美国食品药品监督管理局(FDA)批准了其新型AMZEEQ(米诺环素,占4%)局部用泡沫剂,用于治疗9岁及以上的非结节性中度至重度寻常性痤疮的炎性病变,并且是首个获得FDA批准的局部米诺环素。

Foamix首席执行官David Domzalski表示:"FDA批准AMZEEQ是皮肤病学上的一个里程碑,是近50年来米诺环素的最重大进步。"

米诺环素是一种广谱抗生素,因其治疗中度至重度痤疮的功效而着称,但由于口服时的全身性副作用,在某些患者中的使用受到限制。迄今为止,由于米诺环素在传统的局部用制剂中不稳定,因此尚未作为局部用药。在AMZEEQ中,Foamix利用了其专有的分子稳定技术(MST)平台,可在泡沫剂中有效地提供米诺环素。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1796959, encodeId=d86b1e969598b, content=<a href='/topic/show?id=649f22150ca' target=_blank style='color:#2F92EE;'>#中度至重度痤疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22150, encryptionId=649f22150ca, topicName=中度至重度痤疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Sat Apr 25 13:02:00 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796917, encodeId=95c31e969177e, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Dec 19 12:02:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839732, encodeId=83021839e3262, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sat May 16 07:02:00 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405939, encodeId=4db61405939da, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Mon Oct 21 08:02:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441216, encodeId=32251441216e9, content=<a href='/topic/show?id=0172e6110bf' target=_blank style='color:#2F92EE;'>#米诺环素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76110, encryptionId=0172e6110bf, topicName=米诺环素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12284802660, createdName=ms5880526374914242, createdTime=Mon Oct 21 08:02:00 CST 2019, time=2019-10-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1796959, encodeId=d86b1e969598b, content=<a href='/topic/show?id=649f22150ca' target=_blank style='color:#2F92EE;'>#中度至重度痤疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22150, encryptionId=649f22150ca, topicName=中度至重度痤疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Sat Apr 25 13:02:00 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796917, encodeId=95c31e969177e, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Dec 19 12:02:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839732, encodeId=83021839e3262, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sat May 16 07:02:00 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405939, encodeId=4db61405939da, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Mon Oct 21 08:02:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441216, encodeId=32251441216e9, content=<a href='/topic/show?id=0172e6110bf' target=_blank style='color:#2F92EE;'>#米诺环素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76110, encryptionId=0172e6110bf, topicName=米诺环素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12284802660, createdName=ms5880526374914242, createdTime=Mon Oct 21 08:02:00 CST 2019, time=2019-10-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1796959, encodeId=d86b1e969598b, content=<a href='/topic/show?id=649f22150ca' target=_blank style='color:#2F92EE;'>#中度至重度痤疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22150, encryptionId=649f22150ca, topicName=中度至重度痤疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Sat Apr 25 13:02:00 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796917, encodeId=95c31e969177e, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Dec 19 12:02:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839732, encodeId=83021839e3262, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sat May 16 07:02:00 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405939, encodeId=4db61405939da, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Mon Oct 21 08:02:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441216, encodeId=32251441216e9, content=<a href='/topic/show?id=0172e6110bf' target=_blank style='color:#2F92EE;'>#米诺环素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76110, encryptionId=0172e6110bf, topicName=米诺环素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12284802660, createdName=ms5880526374914242, createdTime=Mon Oct 21 08:02:00 CST 2019, time=2019-10-21, status=1, ipAttribution=)]
    2020-05-16 bugit
  4. [GetPortalCommentsPageByObjectIdResponse(id=1796959, encodeId=d86b1e969598b, content=<a href='/topic/show?id=649f22150ca' target=_blank style='color:#2F92EE;'>#中度至重度痤疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22150, encryptionId=649f22150ca, topicName=中度至重度痤疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Sat Apr 25 13:02:00 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796917, encodeId=95c31e969177e, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Dec 19 12:02:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839732, encodeId=83021839e3262, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sat May 16 07:02:00 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405939, encodeId=4db61405939da, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Mon Oct 21 08:02:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441216, encodeId=32251441216e9, content=<a href='/topic/show?id=0172e6110bf' target=_blank style='color:#2F92EE;'>#米诺环素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76110, encryptionId=0172e6110bf, topicName=米诺环素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12284802660, createdName=ms5880526374914242, createdTime=Mon Oct 21 08:02:00 CST 2019, time=2019-10-21, status=1, ipAttribution=)]
    2019-10-21 chg122
  5. [GetPortalCommentsPageByObjectIdResponse(id=1796959, encodeId=d86b1e969598b, content=<a href='/topic/show?id=649f22150ca' target=_blank style='color:#2F92EE;'>#中度至重度痤疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22150, encryptionId=649f22150ca, topicName=中度至重度痤疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Sat Apr 25 13:02:00 CST 2020, time=2020-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796917, encodeId=95c31e969177e, content=<a href='/topic/show?id=bf162214668' target=_blank style='color:#2F92EE;'>#中度至重度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22146, encryptionId=bf162214668, topicName=中度至重度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Dec 19 12:02:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1839732, encodeId=83021839e3262, content=<a href='/topic/show?id=341ae311ea' target=_blank style='color:#2F92EE;'>#FDA批准#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7311, encryptionId=341ae311ea, topicName=FDA批准)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sat May 16 07:02:00 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405939, encodeId=4db61405939da, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Mon Oct 21 08:02:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441216, encodeId=32251441216e9, content=<a href='/topic/show?id=0172e6110bf' target=_blank style='color:#2F92EE;'>#米诺环素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76110, encryptionId=0172e6110bf, topicName=米诺环素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=12284802660, createdName=ms5880526374914242, createdTime=Mon Oct 21 08:02:00 CST 2019, time=2019-10-21, status=1, ipAttribution=)]